Three people with lasting symptoms after a brain injury went through a six-week iboga microdosing protocol paired with therapy. Two improved and held those gains. One relapsed. A new case series in Frontiers in Pharmacology is going to circulate widely—here’s what it can and can’t tell us, why the dose question matters, and where the sourcing gets uncomfortable.
The post Three Brain Injuries, One Iboga Protocol, and What It Tells Us appeared first on Psychedelics Today.
